**RESEARCH ARTICLE**

Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis

**Eric N. Ouattara¹,²,³, Rachel L. MacLean⁴, Christine Danel¹,³, Ethan D. Borre⁴, Delphine Gabillard¹, Mingshu Huang⁴, Raoul Moh⁵, A. David Paltiel⁶, Serge P. Ehloï², Rochelle P. Walensky⁴,⁶,⁷,⁸,⁹, Xavier Anglaret¹,³, Kenneth A. Freedberg*,¹,²,⁶,⁷,⁸,¹⁰,¹¹**

¹Centre Inserm 1219, University of Bordeaux, Bordeaux, France, ²Interdepartmental Centre of Tropical Medicine and Clinical International Health, Division of Infectious and Tropical Diseases, Department of Medicine, University Hospital Centre, Bordeaux, France, ³Programme PAC-CI/ANRS Research Site, CHU de Treichville, Abidjan, Côte d’Ivoire, ⁴Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America, ⁵Yale School of Public Health, New Haven, CT, United States of America, ⁶Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States of America, ⁷Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States of America, ⁸Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, United States of America, ⁹Division of Infectious Disease, Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA, United States of America, ¹⁰Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America, ¹¹Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States of America

* kfreedberg@mgh.harvard.edu

**Abstract**

**Introduction**

The Temprano and START trials provided evidence to support early ART initiation recommendations. We projected long-term clinical and economic outcomes of immediate ART initiation in Côte d’Ivoire.

**Methods**

We used a mathematical model to compare three potential ART initiation criteria: 1) CD4 <350/μL (ART <350/μL); 2) CD4 <500/μL (ART <500/μL); and 3) ART at presentation (Immediate ART). Outcomes from the model included life expectancy, 10-year medical resource use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/μL, SD 198/μL) and transmitted cases. Key input parameters to the analysis included first-line ART efficacy (80% suppression at 6 months) and ART cost ($90/person-year).

**Results**

Immediate ART increased life expectancy by 0.34 years compared to ART <350/μL and 0.17 years compared to ART <500/μL. Immediate ART resulted in 4,500 fewer 10-year
transmissions per 170,000 PWH compared to ART<350/μL. In cost-effectiveness analysis, Immediate ART had a 10-year ICER of $680/YLS compared to ART<350/μL, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. ART<500/μL was “dominated” (an inefficient use of resources), compared with Immediate ART. Immediate ART increased the 5-year HIV care budget from $801.9M to $812.6M compared to ART<350/μL.

Conclusions

In Côte d’Ivoire, immediate compared to later ART initiation will increase life expectancy, decrease HIV transmission, and be cost-effective over the long-term, with modest budget impact. Immediate ART initiation is an appropriate, high-value standard of care in Côte d’Ivoire and similar settings.

Introduction

Although international guidelines recommend immediate ART initiation for persons with HIV infection, many patients in sub-Saharan Africa commonly start ART with advanced disease, when they already face high morbidity and mortality risk [1]. Timing of ART initiation has been a debate in HIV clinical care and policy, particularly in resource-limited settings [2, 3]. Multiple clinical trials over the past decade prompted the World Health Organization (WHO) to change the CD4 threshold for ART initiation, from <200 cells/μL in 2006 to <350 cells/μL in 2010 and then to <500 cells/μL in 2013 [4–6]. In 2015, the Temprano (Côte d’Ivoire) and START (multi-country) trials showed a 44–58% reduction in mortality or serious HIV-related illnesses in people with HIV who initiated ART immediately at presentation regardless of CD4 count compared to those who deferred initiation [7, 8]. In response to these trials, WHO modified its guidelines in 2015 to recommend ART initiation at diagnosis for all people with HIV [9].

While most resource-limited countries have adopted immediate treatment, not all have fully implemented this recommendation, generally due to budget constraints and concerns about long-term affordability for all those with HIV [10]. While the Temprano and START trials showed the short-term clinical benefits of immediate ART initiation in study settings, the longer-term clinical and economic outcomes of national implementation of immediate ART initiation in Côte d’Ivoire and similar settings remain unknown. We addressed these questions by conducting a cost-effectiveness and budget impact assessment of immediate compared to delayed ART initiation in people with HIV in care and initiating care in Côte d’Ivoire.

Methods

Analytic overview

We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International microsimulation model to assess the clinical benefits, cost-effectiveness, and budget impact of different ART initiation thresholds in a nationally representative cohort of people with HIV-1 in Côte d’Ivoire [11, 12]. We evaluated the following three ART initiation strategies: 1) CD4 count <350/μL or WHO stage 3–4 (ART<350/μL, until 2013 the standard of care in Côte d’Ivoire); 2) CD4 count <500/μL or WHO stage 3–4 (ART<500/μL, the standard of care in Côte d’Ivoire until April, 2017) [10]; or 3) ART initiation when patients present to care, regardless of CD4 count (Immediate ART), the current WHO recommendation and recent
guideline in Côte d’Ivoire [9, 13]. We simulated these strategies for the population of people with HIV in care in Côte d’Ivoire.

We projected several outcomes: life expectancy from time of presentation to care; cumulative 10-year HIV transmissions; 5- and 10-year total medical resource use; and 10-year cumulative life-years saved; and 10-year incremental cost-effectiveness ratios (ICERs) in 2017 US dollars per year of life saved (YLS). To assess budget impact, we projected 5- and 10-year HIV-related expenditures for Immediate ART compared to ART<500/μL and ART<350/μL for people with HIV in care and those projected to initiate ART from 2017–2021 in Côte d’Ivoire. Cost-effectiveness and budget impact also accounted for transmitted cases of HIV. When reported for purposes of economic evaluation, all outcomes were discounted at a rate of 3% per year. In accordance with convention, budget impact results were reported undiscounted [14]. We defined a strategy as cost-effective if its ICER was less than $1,600/YLS, the 2017 annual per capita GDP in Côte d’Ivoire [15].

Cohort description

Population included in the cost-effectiveness analysis. For the cost-effectiveness analysis, we began by modeling the 170,000 persons currently in care in Côte d’Ivoire, as well as all incident transmitted cases from this cohort (first-generation and later-generation transmissions over 10 years, S1A Fig). Incident cases began unlinked to care, with characteristics of a newly-infected population, and presented to care through routine HIV screening or clinical presentation with an opportunistic disease (OD) [16].

Population included in the budget impact analysis. For the budget impact analysis, we included all those in care and entering care in the next 5 years in Côte d’Ivoire. To estimate the number expected to enter care each year (the "present to care" cohort), we began with historical data showing a yearly average of 14,000 people entering HIV care in Côte d’Ivoire [17]. For the Immediate ART and the ART<500/μL strategies, we subtracted the number of transmissions prevented compared with the ART<350/μL strategy from 14,000 to estimate the “present to care” cohort size (S1B Fig).

The CEPAC-International model

Disease model. CEPAC-International is a microsimulation model of HIV natural history, disease progression, and treatment [12, 18]. Simulated patients are followed monthly from model entry until death and are generated from user-specified distributions of initial age, sex, initial CD4 count, HIV RNA, treatment adherence, and OD history. People with HIV who enter the model not in care can link to care through presentation with an OD or a monthly probability of having an HIV test and presenting to care. ART is initiated according to strategy-specific CD4 count thresholds or based on an OD. Effective ART reduces HIV RNA and increases CD4 count; CD4 count determines risk of ODs and death [19, 20]. Additional details of the model are published and online at http://web2.research.partners.org/cepac [18, 21, 22].

Transmission model. We modeled HIV transmission dependent on stage of infection (acute, chronic, or end-stage disease) and HIV RNA [23]. The model reports monthly, patient-level HIV RNA; this depends on baseline HIV RNA, stage of infection, and virologic suppression on ART. Summing cumulative viral load across 12 months and linking this to HIV RNA-specific transmission rates determines yearly new infections [23]. In this way, we account for transmissions from the “first generation” cohort, or transmissions from patients that are simulated from model initiation. We also use this method to calculate transmissions from each previous year’s newly-infected cohort for up to 10 years. Outcomes in each subsequent year
include the first-generation cohort as well as all newly infected cohorts from previous years (S1A Fig).

Model input data

Cohort characteristics and natural history. Simulated people with HIV in care in Côte d’Ivoire had a mean initial CD4 count of 259/μL (SD: 198/μL) (Table 1). Age and sex distributions were from the PRECO-CI cohort [16], a nationally representative cohort of people with HIV in care in Côte d’Ivoire, where the majority of people in care have CD4 counts <500/μL (88%). Initial HIV RNA distribution was from the Temprano trial [7]. The incidence of tuberculosis (TB) for people with HIV at CD4 counts >350/μL was also derived from the Temprano trial, which closely captured TB incidence data at high CD4 counts [7, 19]. Other natural history characteristics were from published cohort studies of the HIV-infected population in Côte d’Ivoire [19, 24–26]. Transmitted cases began the simulation with characteristics of a newly-infected cohort (high CD4 count, no prior OD history) and were diagnosed and linked to care, with subsequent treatment as described below, at a mean CD4 count of 259 cells/μL based on current HIV testing and presentation data [16].

ART regimen. Overall six-month virologic suppression was 80% for both 1st-line (tenofovir and lamivudine plus efavirenz) and 2nd-line ART (zidovudine and lamivudine plus lopinavir/ritonavir) regimens. This reflects current 1st-line ART and levels of virologic suppression in clinical settings in Côte d’Ivoire [25]. Probability of later failure after initial suppression was 0.13–9.0%/month, depending on adherence [12]. After failure on either regimen, patients received an adherence intervention, with a 54% probability of viral resuppression, consistent with current approaches to management [35]. Guideline-concordant care for Côte d’Ivoire included twice-yearly CD4 tests, with HIV RNA confirmation of CD4-defined treatment failure [6, 13].

Transmission. Aggregated transmission probabilities by HIV RNA stratum ranged from 0.16/100PY for HIV RNA <500 copies/mL to 9.03/100PY for HIV RNA >100,000 copies/mL [23]. Transmission was increased during the 6-month period of acute HIV infection (65.47/100PY) and during end-stage disease off ART with CD4 <200/μL (9.03/100PY) [32].

Cost inputs. Cost inputs to the model included all direct HIV-related medical costs. ART costs were based on Clinton Health Access Initiative prices and included $90/person/year for first-line ART and $282/person/year for second-line therapy [33, 34]. OD treatment costs ranged from $80–$555 and CD4-stratified care costs from Côte d’Ivoire ranged from $37–$50/month [36]. We used Côte d’Ivoire-specific GDP deflators and the average 2017 exchange rate to convert all cost inputs to constant 2017 US dollars (USD) [15]. The analysis was conducted from a modified societal perspective (not including patient time costs).

Sensitivity analyses

We assessed key input parameters in sensitivity analysis to evaluate the robustness of our findings to plausible variation in these parameters (ranges in Table 1). Combining influential parameters identified in one-way sensitivity analyses, we simultaneously varied multiple input parameters to determine their combined impact on the results. In the base-case analysis, we assumed no effect of changing ART initiation criteria on overall HIV testing rates. We tested this assumption in sensitivity analysis by increasing the mean CD4 count at diagnosis for new infections, as might occur if HIV testing rates increased.

Ethics statement

The CEPAC Data Repository was approved by the Massachusetts General Hospital IRB (2014P002708/MGH). Within the CEPAC Data Repository, all data are collected by outside
Table 1. Main input parameters for an analysis of the cost-effectiveness of immediate ART for HIV infection in Côte d'Ivoire.

| Parameter                                                                 | Base-case value | Range evaluated | Reference |
|---------------------------------------------------------------------------|-----------------|-----------------|-----------|
| **Cohort characteristics**                                               |                 |                 |           |
| Sex, female/male, %                                                       | 68/32           | —               | [16]      |
| Age, mean (SD) years                                                      | 37 (9)          | 18–55           | [16]      |
| CD4, mean (SD) cells/μl (Total Cohort)                                   | 259 (198)       | 146–388         | [16]      |
| Plasma HIV-1 RNA distribution, copies/mL %                               |                 |                 | [7]       |
| >100,000                                                                  | 34              | —               |           |
| 30,001–10,000                                                             | 24              | —               |           |
| 10,001–30,000                                                             | 17              | —               |           |
| 3,001–10,000                                                              | 13              | —               |           |
| 501–3,000                                                                 | 8               | —               |           |
| 50–500                                                                    | 3               | —               |           |
| < 49                                                                      | 1               | —               |           |
| **Monthly probability of morbidity and mortality, off ART, % $$**         |                 |                 |           |
| Monthly OD rates (non-TB)                                                 | 0.01–9.0        | —               | [19, 27]  |
| Monthly TB rates                                                           | 0.2–0.7         | —               | [7, 27]   |
| Acute mortality from OD                                                   | 0.0–16.7        | —               | [19, 27]  |
| Acute mortality from TB                                                   | 6.5–50.0        | —               | [19, 27]  |
| Monthly probability of death from HIV                                     | 0.04–5.4        | —               | [27]      |
| **ART efficacy, toxicity, and loss to follow-up**                         |                 |                 |           |
| First-line ART**                                                          |                 |                 |           |
| HIV-1 RNA suppression at 6 months, mean %                                 | 80              | 50–90           | [25]      |
| Virologic failure after 6 months, per 100 PY                             | 15              | 7–22            | [25]      |
| Adherence <65%**                                                           | 93              | —               | [25]      |
| Adherence >95%                                                            | 1.6             | —               | [25]      |
| Monthly CD4 increase for those suppressed, mean (SD) cell/μl              |                 |                 |           |
| Between 0 and 2 months                                                   | 76 (19)         | —               | [25]      |
| ≥ 3 months                                                                | 4 (1)           | —               | [25]      |
| Toxicity, %                                                               |                 |                 |           |
| Minor                                                                     | 11              | —               | [28]      |
| Major                                                                     | 5               | —               | [29]      |
| Toxicity-related mortality, %                                             | 0.6             | —               | [28, 29]  |
| **Loss to follow-up, per 100 PY**                                         |                 |                 |           |
| Adherence <65%                                                            | 13              | 6–17            | [30, 31]  |
| Adherence >95%                                                            | 1.9             | 5–14            |           |
| **Transmission rates (per 100 PY), by disease stage and viral load**      |                 |                 |           |
| Incident infection (6 months post infection)**                            | 65.47           | 28.06–152.90    | [23, 32]  |
| Late stage disease (CD4 <200 cells/μL)                                    | 9.03            | 3.87–21.09      |           |
| >100,000 copies/mL                                                        | 9.03            | 3.87–21.09      |           |
| 10,001–100,000 copies/mL                                                  | 8.12            | 2.78–23.77      |           |
| 3,001–10,000 copies/mL                                                    | 4.17            | 0.84–20.65      |           |
| 501–3,000 copies/mL                                                       | 2.06            | 0.57–7.47       |           |
| 0–500 copies/mL                                                           | 0.16            | 0.02–1.13       |           |
| **Costs, 2017 USD**                                                       |                 |                 |           |
| ART, annual                                                               |                 |                 | [33, 34]  |
| 1st-line ART                                                              | 90              | 45–135          |           |
| 2nd-line ART                                                              | 282             | 141–423         |           |
| Prophylaxis, annual                                                       |                 |                 |           |

(Continued)
entities and shared with investigators after a quality check by a compliance specialist to ensure that they meet all specifications of the Data Use Agreement and that all identifiers are removed. The Temprano data set and consent form were included in the CEPAC Data Repository at the time of the initial approval of the protocol. The Temprano trial protocol was approved by the Coˆte d’Ivoire Minister of Health and Public Hygiene and the Coˆte d’Ivoire National Ethics Committee for Life Sciences and Health (/MSHP/CAB/CNESV S/06). The Temprano dataset as received from the collaborators in Coˆte d’Ivoire did not contain any Protected Health Information. The dataset as received contained limited indirect identifiers necessary for the analyses, but it was stored in a restricted secure network drive to which only named CEPAC investigators and biostatisticians have access. The biostatistical team generated completely anonymized aggregate inputs to be used in the model, which were then made available to the larger study team. As the research project was limited to use of existing secondary data provided by the Temprano investigators in a de-identified format, the Partners Human Research Committee waived the requirement for informed consent.

Results

Clinical outcomes

Discounted life expectancy from presentation to care increased from 16.05 years with ART <350/μL to 16.22 with ART at 500/μL and to 16.39 years with Immediate ART (Table 2A). Cumulative transmissions arising from the 170,000 persons in care and their transmitted cases over 10 years decreased from 47,500 with ART <350/μL to 43,000 with Immediate ART, a decrease of 9.8% (Table 2A and Fig 3 bottom). Because most people in care in Coˆte d’Ivoire have a CD4 count <350/μL, there were 22,780 people with CD4 counts 350-500/μL and 20,400 people with CD4 counts >500/μL at simulation start; thus the Immediate ART strategy changed care in 12% of the in-care population. When we included life-years saved from transmissions averted over 10 years and compared total life-years to ART <350/μL, ART <500/μL saved 12,000 years of life and Immediate ART saved an additional 4,000 years of life (both discounted).

Costs and cost-effectiveness analysis

Over 10 years, total discounted costs increased from $1.057 billion with ART <350/μL to $1.065 billion for ART <500/μL and to $1.068 billion with Immediate ART. Compared to

Table 1. (Continued)

| Parameter                          | Base-case value | Range evaluated | Reference |
|------------------------------------|-----------------|-----------------|-----------|
| Co-trimoxazole                     | 27              | —               | [18]      |
| Laboratory monitoring, per test    |                 |                 | CeDReS    |
| CD4 test                           | 13              | —               | CeDReS    |
| HIV RNA test                       | 40              | —               | CeDReS    |
| OD treatment costs (range by OD)   | 80–555          |                 | [18]      |

ART: antiretroviral therapy; SD: standard deviation; USD: 2017 US dollars; PY: person-years; CeDReS: Centre de diagnostic et de Recherche sur le SIDA et les Affections Opportunistes at Treichville University Hospital, Abidjan, Coˆte d’Ivoire; OD: opportunistic disease

§ Morbidity and mortality ranges in patients from higher to lower mean CD4 strata

*1st-line ART: tenofovir + lamivudine + efavirenz

**Based on Medication Possession Ratio [25]

†The transmission rate for incident infection is derived as 7.25*9.03 [23, 32]
ART<350/μL, Immediate ART was cost-effective with an ICER of $680/YLS, well below the annual per capita GDP in Côte d’Ivoire (Table 2, undiscounted results in S1 Table). ART<500/μL had a higher ICER than Immediate ART (ICER $680/YLS compared to ART<350/μL) and by convention, we labeled this strategy “dominated,” or an inefficient use of economic resources.

### Sensitivity analyses

#### One-way sensitivity analyses

In one-way sensitivity analyses, with variation across plausible input ranges, the ICER for Immediate ART compared to ART<350/μL, as well as to ART<500/μL, remained below the annual Côte d’Ivoire per capita GDP (Fig 1). ART<500/μL was no longer a “dominated” strategy if costs of 1st- and 2nd-line ART were higher, mean CD4 count at diagnosis for the prevalent cohort was lower, or HIV transmission rates were lower († in Fig 1). Compared to ART<350/μL, the cost-effectiveness of Immediate ART was most sensitive to HIV transmission rates stratified by HIV RNA level, first-line ART cost, and first-line ART efficacy at presentation for incident cases.

When we varied transmission rates across their literature-based 95% CI (3.28–9.70/100PY), Immediate ART ranged from cost-saving to an ICER of $1,440/YLS; with higher transmission rates Immediate ART was more cost-effective. When 1st-line ART costs were varied from $45-135/year (base-case: $90/year), the ICER ranged from $380/YLS to $1,050/YLS. Immediate ART became more cost-effective (ICER $330/YLS) with higher CD4 count at diagnosis for incident cases (574 cells/μL), as might be the case with increased testing, and less cost-effective (ICER $750/YLS) with lower CD4 count at diagnosis (221 cells/μL), if testing were to decrease.
Multi-way sensitivity analyses. We simultaneously varied transmission rates, mean CD4 count at diagnosis for incident cases, and first-line ART cost across wide ranges (Fig 2). When we held each of these at their base-case values, increasing transmission rates 1.9-fold or more made Immediate ART cost-saving (Fig 2, panel B). If the cost of first-line ART was lowered to $75/year, no combination of input parameter variation resulted in an ICER for Immediate ART above $1,600, Côte d’Ivoire’s 2017 annual per capita GDP (Fig 2, panel A). Only if ART costs increased 1.5-fold and transmission rates decreased to less than 0.7-fold did the ICER for Immediate ART rise above the Côte d’Ivoire annual per capita GDP (Fig 2, Panel C).

Transmissions and budget impact
At 5 years, ART<500/μL and Immediate ART increased the budget compared to ART<350/μL by 0.88% and 1.33%, from $801.9 million to $809.0 million and $812.6 million (undiscounted). The annual expenditures over the first 5 years for ART<500/μL compared to ART<350/μL ranged from $1.0 million to $2.5 million and for Immediate ART compared to ART<350/μL ranged from $1.4 million to $4.4 million (S4 Table). In the Immediate ART strategy at 5 years, laboratory monitoring costs increased by 0.2% and ART costs increased by 1.2% compared to ART<350/μL; other HIV care costs did not change substantially (S2 Fig).

Delayed ART initiation increases both morbidity and mortality, as observed by the greater number of life-years gained from immediate ART initiation compared with delayed initiation (ART<500/μL) across initial CD4 counts (S2 Table). As the mean CD4 count at presentation to care of the incident cohorts increases, newly-infected patients spend more time in care and
waiting to meet treatment criteria with the delayed ART strategies, while at risk of developing
ODs and incurring additional treatment costs. Thus, the total costs of \( \text{ART} < 500/\mu \text{L} \) approach
and then exceed the total costs of \text{Immediate ART} as the mean CD4 counts of the incident
cohorts increase, as would likely be seen with increased testing (S2 Table). Over 10 years, the
\text{Immediate ART} strategy also had a larger impact on decreasing transmissions than on increas-
ing the budget; these differences became even more pronounced as the CD4 count at diagnosis
increased (Fig 3).

**Discussion**

We assessed the clinical impact, cost-effectiveness, and budget impact of immediate ART initia-
tion for all people with HIV currently in care in Côte d’Ivoire, regardless of CD4 count, as
well as those presenting to HIV care over the next 5 years. The latest HIV treatment guidelines
Cost-effectiveness and budget impact of immediate ART in Côte d’Ivoire recommend immediate ART for all people with HIV; this analysis used nationally representative data to evaluate this guideline change. Our analysis had three main findings.

First, compared to $\text{ART}<350/\mu\text{L}$, Immediate ART improved overall discounted life expectancy from presentation to care (from 16.05 years to 16.39 years) and reduced HIV transmissions over 10 years (from 47,500 to 43,000). Second, Immediate ART is cost-effective compared to both $\text{ART}<350/\mu\text{L}$ and $\text{ART}<500/\mu\text{L}$. While the increases in life expectancy are relatively small, particularly when averaged across all persons already in care, the increases in costs are also small, since most people with HIV in care in Côte d’Ivoire are already on ART.

https://doi.org/10.1371/journal.pone.0219068.g003
and Immediate ART will prevent additional transmissions, thus avoiding future care costs. When we examined the 170,000 people with HIV in care in Côte d’Ivoire, and their transmitted cases, the incremental cost-effectiveness ratio for Immediate ART compared to ART<350/μL was $680/YLS, less than half the per capita GDP in Côte d’Ivoire ($1,600). Third, compared to ART<350μL, Immediate ART increased the 5-year HIV budget in Côte d’Ivoire by 1.3%, a modest increase that accounted for current patients, as well as those newly-diagnosed and likely to enter care during the subsequent five years.

Our cost-effectiveness conclusions were robust to wide variations in key clinical characteristics and costs. When single parameters were varied, the ICER of Immediate ART never exceeded the per capita GDP in Côte d’Ivoire. In multiway sensitivity analyses, the ICER of Immediate ART remained below $1,600/YLS for plausible combinations of transmission rates, CD4 counts at diagnosis for incident cases, and first-line ART efficacies. Only if ART costs increased by 1.5-fold did the ICER begin to exceed the Côte d’Ivoire per capita GDP. However, as ART costs in resource-limited settings have historically decreased over time, this is unlikely. Further, even new integrase-inhibitor based regimens are now being priced at $75/person/year in many resource-limited settings [37]; if this occurs in Côte d’Ivoire Immediate ART would be even more cost-effective. Finally, if we examine a longer time horizon than 10 years, Immediate ART becomes even more cost-effective. At 15 years, the ICER for Immediate ART compared to ART<350/μL decreases to $330/YLS (from $680/YLS at 10 years); at 20 years, the ICER for Immediate ART further decreases to $250/YLS.

This study adds to the growing literature demonstrating the clinical benefit and cost-effectiveness of earlier ART initiation among HIV-infected individuals [38, 39]. Similar to our findings, they found immediate ART to be cost-effective or cost-saving. Kuznik et al. used a Markov model to examine immediate ART in South Africa, Nigeria, Uganda, and India, and found that immediate ART would be either cost-saving or cost-effective using a 1X per capita GDP threshold [40]. McCreesh et al. similarly found immediate ART to be cost-effective by similar criteria in a model focused in Uganda [41]. Our analysis also complements the clinical findings of the Temprano trial. We demonstrate additional projected long-term clinical benefit and economic value to Immediate ART compared to ART<500/μL.

A major concern regarding immediate ART provision is the budget impact associated with treating all patients. We found that the 5-year budget impact of Immediate ART as a strategy compared to ART<350/μL is modest in the context of the overall HIV program in Côte d’Ivoire (1.3% increase, or $10.7M). This is because many people with CD4 counts >350/μL in Côte d’Ivoire, and elsewhere, have not yet been tested for HIV and are not in care; additionally, most of those currently tested do not have CD4 counts >500/μL. If Immediate ART were combined with increased HIV testing efforts, resulting in a higher mean CD4 count at linkage to care, we found, however, that the absolute budget impact of Immediate ART would be even less. This is due to savings from preventing opportunistic diseases, such as tuberculosis and bacterial infections, which are the most common complications in Côte d’Ivoire and similar settings in people with higher CD4 counts, as well as preventing HIV transmissions. In fact, recent evidence suggests that increasing ART availability may itself increase the number of patients seeking HIV testing, even without any testing-specific interventions [42].

This analysis has several limitations. First, simulation models necessarily simplify complex biological processes and procedures, and not all data are available from a single setting. We used transmission rates from published meta-analyses, rather than specifically from Côte d’Ivoire. We found, however, that the cost-effectiveness conclusions were robust to variations in these rates. Second, we derived clinical care costs from a single setting in Côte d’Ivoire. The results did not change even when we varied these costs widely. Third, we did not specifically account for NNRTI resistance in the model. The immediate ART strategy, however, remained
cost-effective even with lower ART efficacy, as might be found with primary drug resistance. In the cost-effectiveness analysis, we examined outcomes only for individuals in HIV care and their transmitted cases. As a result, our transmission projections do not include those occurring from people not in care. There was no material change in the qualitative findings and conclusions of the cost-effectiveness analysis when we varied the number of transmissions included. We also did not adjust for health-related quality of life in this analysis. Since additional years lived will be in less than perfect health, our costs per year of life saved would be lower than cost per quality-adjusted life-year (QALY) or disability-adjusted life-year. However, if immediate ART increases quality of life in addition to improving survival, our costs per year of life saved would be higher than cost per QALY. It is also not clear that there is a strong relationship between CD4 count and health-related quality of life in the current era of effective ART [43, 44]. Thus, readers should interpret our comparison to the WHO-CHOICE GDP threshold with caution. Finally, we did not specifically include the cost of any increased testing, which would further increase the number of people in care in Côte d’Ivoire. However, we and others have shown that HIV testing itself is highly cost-effective in multiple settings, including those with both higher and lower prevalence than in Côte d’Ivoire [45–48]. In this analysis, even if increased testing increased the CD4 count at presentation, Immediate ART would remain cost-effective. As the number of people in care increased, total outlays would also increase.

The pressing question of ‘when to treat’ HIV-infected individuals in resource-limited settings has been answered in recent clinical trials, with immediate ART treatment demonstrating clear short-term clinical superiority over delayed treatment strategies [6–8]. In this analysis, we aimed to assess the longer-term clinical and economic implications of immediate ART initiation, focusing on Côte d’Ivoire, a nation with high HIV prevalence in West Africa. We found that ART initiation at presentation would increase life expectancy, decrease HIV transmissions, and be highly cost-effective, all with a modest budget impact over 5 years. Immediate ART is an appropriate standard of care in Côte d’Ivoire and similar countries in sub-Saharan Africa and should be fully implemented.

Supporting information

S1 Fig. Populations modeled in the cost-effectiveness and budgetary impact analyses of a model-based analysis of early ART initiation in Côte d’Ivoire. The populations included in the cost-effectiveness analysis (Panel A) were the 170,000 persons currently in care in Côte d’Ivoire (CI) as well as all transmitted cases arising from this population (including first generation and higher order transmissions). We restricted the population modeled to persons in care, and their transmitted cases, excluding persons with undiagnosed HIV, to isolate the effect of a policy change regarding ART initiation criteria. The populations modeled in the budget impact analysis (Panel B) included the 170,000 persons currently in care in Côte d’Ivoire and their transmitted cases, as well as persons newly presenting to care each year over the next five years. Each outlined box represents the entry of the specified cohort into the analysis. To estimate the number expected to enter care each year over the next 5 years (the “present to care” cohort), we began with historical data showing a yearly average of 14,000 people entering HIV care in Côte d’Ivoire [17]. For the Immediate ART and the ART<500/µL strategies, we subtracted from the 14,000 the number of transmissions prevented compared with the ART<350/µL strategy. Because the ART<350/µL cohort has the most transmissions of the strategies modeled, any transmissions averted by ART<500/µL and Immediate ART are excluded in the budget impact analysis for those strategies. We included an estimate of the costs of undiagnosed persons presenting to care in Côte d’Ivoire in the budget impact analysis to better project total
HIV program costs under the different ART initiation thresholds.

S2 Fig. 5-year budget impact of ART at CD4 counts <500/μL and immediate ART initiation compared to ART at CD4 counts <350/μL in Côte d’Ivoire. Each bar represents the 5-year proportional budget impact of ART<500/μL (left) and Immediate ART (right) compared to ART<350/μL. The height of the bars represents the impact on the total budget, measured in % budget increase compared to ART<350/μL. The change in other HIV care costs (orange), laboratory monitoring costs (blue), and ART costs (green) are also shown as a proportion of the change in total costs compared to ART<350/μL. Most of the budget increases for ART<500/μL and Immediate ART at 5 years are in ART costs. ART: antiretroviral therapy.

S1 Table. Undiscounted clinical and economic outcomes of ART initiation according to CD4 threshold or immediate ART initiation in Côte d’Ivoire, corollary to Table 2.

S2 Table. Sensitivity analysis of mean CD4 at diagnosis for incident cohorts in evaluation of clinical and economic outcomes of ART initiation according to CD4 threshold or immediate ART initiation in Côte d’Ivoire.

S3 Table. 15- and 20-year clinical and economic outcomes of ART initiation according to CD4 threshold or immediate ART initiation in Côte d’Ivoire.

S4 Table. 5-year annual budget impact, 2017 USD, in millions.

Acknowledgments

The authors would like to thank Naomi F. Fields, Lucia R.I. Millham, and Julia H.A. Foote for technical and manuscript support and Taige Hou for CEPAC model development.

Author Contributions

Conceptualization: Eric N. Ouattara, Christine Danel, Xavier Anglaret, Kenneth A. Freedberg.

Data curation: Eric N. Ouattara, Rachel L. MacLean, Christine Danel, Delphine Gabillard, Raoul Moh, Serge P. Eholié, Xavier Anglaret.

Formal analysis: Eric N. Ouattara, Rachel L. MacLean, Ethan D. Borre, Delphine Gabillard, Mingshu Huang, A. David Paltiel, Rochelle P. Walensky, Xavier Anglaret, Kenneth A. Freedberg.

Funding acquisition: Eric N. Ouattara, Christine Danel, Delphine Gabillard, Serge P. Eholié, Rochelle P. Walensky, Xavier Anglaret, Kenneth A. Freedberg.

Methodology: Eric N. Ouattara, Rachel L. MacLean, Ethan D. Borre, A. David Paltiel, Rochelle P. Walensky, Xavier Anglaret, Kenneth A. Freedberg.

Supervision: Kenneth A. Freedberg.
References

1. IeDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis. 2018 Mar 15; 66(6):893–903. https://doi.org/10.1093/cid/cix915 PMID: 29373672

2. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010 Jul 15; 363(3):257–65. https://doi.org/10.1056/NEJMoa0910370 PMID: 20647201

3. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281–90. https://doi.org/10.1016/S1473-3099(13)70892-3 PMID: 24602844

4. World Health Organization. 2006. Antiretroviral therapy For HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Accessed 24 May 2019 at http://www.who.int/hiv/pub/guidelines/adultguidelines.pdf.

5. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents; recommendations for a public health approach (2010 version). Accessed 24 May 2019 at http://www.who.int/hiv/pub/adult2010/en/index.html.

6. World Health Organization. 2013. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a Public Health approach. Accessed 12 June 2019 at http://apps.who.int/iris/bitstream/10665/85321/1/9789241506727_eng.pdf.

7. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early antiretroviral and isoniazid preventive therapy in Africa. N Engl J Med. 2015 Aug 27; 373(9):808–22. https://doi.org/10.1056/NEJMoa1507198 PMID: 26193126

8. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9):795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

9. World Health Organization. 2015. Guidelines on when to start antiretroviral therapy and pre-exposure prophylaxis for HIV. Accessed 12 June 2019 at http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1.

10. World Health Organization (WHO). 2017. Treat All: Policy Adoption and Implementation Status in Countries. Geneva, Switzerland: WHO. Accessed 12 June 2019 at apps.who.int/iris/bitstream/10665/259532/1/WHO-HIV-2017.58-eng.pdf.

11. Ouattara EN, Robine M, Eholie SP, MacLean RL, Moh R, Loesina E, et al. Laboratory monitoring of antiretroviral therapy for HIV infection: cost-effectiveness and budget impact of current and novel strategies. Clin Infect Dis. 2016 Jun 1; 62(1):1454–62. https://doi.org/10.1093/cid/ciw17 PMID: 26936666

12. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noufary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715–25. https://doi.org/10.1056/NEJMsa1214720 PMID: 24171517

13. Département de Prise en Charge Programme National de Lutte contre le Sida. Directives nationales PEC adultes et adolescents. 2015.

14. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016 Sep 13; 316(10):1093–103. https://doi.org/10.1001/jama.2016.12195 PMID: 27823463

15. Knoema. Côte d’Ivoire GDP per capita, 1980–2017. Accessed 12 June 2019 at https://knoema.com/atlas/C%C3%A9te-d%27Ivoire/GDP-per-capita.

16. Inghels M, Niangoran S, Menga A, Yoboue JM, Dohoun L, Yao A, et al. Missed opportunities for HIV testing among newly diagnosed HIV-infected adults in Abidjan, Côte d’Ivoire. PLoS One. 2017; 12(10): e0185117. https://doi.org/10.1371/journal.pone.0185117 PMID: 28977006
Cost-effectiveness and budget impact of immediate ART in Côte d’Ivoire

17. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDSinfo. 2017. Accessed 12 June 2019 at http://aidsinfo.unaids.org/.

18. Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, et al. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d’Ivoire. J Acquir Immune Defic Syndr. 2014 Jul 1; 66(3):294–302. https://doi.org/10.1097/QAI.0000000000000166 PMID: 24732870

19. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Côte d’Ivoire. Clin Infect Dis. 2012 Mar 1; 54(5):714–23. https://doi.org/10.1093/cid/cir898 PMID: 22173233

20. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect

21. Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, et al. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013; 18(1):45–55. https://doi.org/10.3851/IMP2231 PMID: 22809695

22. Walensky RP, Borre ED, Becker L-G, Resch SC, Hyle EP, Wood R, et al. The anticipated clinical and economic impact of 90-90-90 in South Africa. Ann Intern Med. 2016; 165(5):325–33. https://doi.org/10.7326/M16-0799 PMID: 27240120

23. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009 Jul 17; 23(11):1397–404. https://doi.org/10.1097/QAD.0b013e3283231a6c PMID: 19381076

24. Danel C, Moh R, Mginga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006 Jun 17; 367(9527):1981–9. https://doi.org/10.1016/S0140-6736(06)68887-9 PMID: 16782488

25. Messou E, Chaix ML, Gabillard D, Mginga A, Losina E, Yapo V, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d’Ivoire. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):356–64. https://doi.org/10.1097/QAI.0b013e3182084b6a PMID: 21191309

26. World Health Organization. 2008. World population prospects: the 2008 revision. Accessed 24 May 2019 at http://www.un.org/esa/population/publications/wpp2008/wpp2008_highlights.pdf.

27. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Accessed 24 May 2019 at http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1.

28. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 Oct 15; 191(6):825–9. https://doi.org/10.1086/428093 PMID: 15717255

29. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campion RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes—a 96-week analysis. J Acquir Immune Defic Syndr. 2006 Dec 15; 43(5):535–40. https://doi.org/10.1097/01.qai.0000245986.51262.67 PMID: 17057609

30. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010 Jun;15 Suppl 1:1–15.

31. Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, et al. The clinical and economic impact of point-of-care CD4 testing in Mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2014 Sep; 11(9):e1001725. https://doi.org/10.1371/journal.pmed.1001725 PMID: 25225800

32. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005 May 1; 191(9):1403–9. https://doi.org/10.1086/429411 PMID: 15808997

33. The Clinton Health Access Initiative (CHAI). 2017. 2017 Antiretroviral (ARV) CHAI reference price list. Accessed 12 June 2019 at https://clintonhealthaccess.org/content/uploads/2017/12/2017-CHAI-ARV-Reference-Price-List_FINAL.pdf.

34. The Clinton Health Access Initiative (CHAI). 2016. 2016 Antiretroviral (ARV) CHAI reference price list. Accessed 12 June 2019 at https://clintonhealthaccess.org/content/uploads/2016/11/2016-CHAI-ARV-Reference-Price-List_FINAL.pdf.

35. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and
adults on antiretroviral therapy for HIV in Swaziland. PloS One. 2015; 10(2):e0116144. https://doi.org/10.1371/journal.pone.0116144 PMID: 25695494

36. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299–308. PMID: 16052085

37. Zheng A, Kumarasamy N, Huang M, Pattiel AD, Mayer KH, Rewari BB, et al. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. Journal of the International AIDS Society. 2018 Mar; 21(3):e25085. https://doi.org/10.1002/jia2.25085 PMID: 29603882

38. Sempa J, Ssennono M, Kuznik A, Lamorde M, Sowinski S, Semeere A, et al. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda. BMC Public Health. 2012; 12:736. https://doi.org/10.1186/1471-2458-12-736 PMID: 22943068

39. Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. J Int AIDS Soc. 2015; 18:20217. https://doi.org/10.7448/IAS.18.1.20217 PMID: 26434780

40. Kuznik A, Ilyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. AIDS. 2016 Nov 28; 30(18):2865–73. https://doi.org/10.1097/QAD.0000000000001251 PMID: 27662547

41. McCreeh N, Andrianakis I, Nsubuga RN, Strong M, Vernon TJ, et al. Improving ART programme retention and viral suppression are key to maximising impact of treatment as prevention—a modelling study. BMC Infect Dis. 2017 Aug 9; 17(1):557. https://doi.org/10.1186/s12879-017-2664-6 PMID: 28793872

42. Wilson N. Antiretroviral therapy and demand for HIV testing: evidence from Zambia. Econ Hum Biol. 2016 Feb 20; 21:221–40. https://doi.org/10.1016/j.ehb.2016.02.003 PMID: 26970992

43. Igumbor J, Stewart A, Holzemew W. Comparison of the health-related quality of life, CD4 count and viral load of AIDS patients and people with HIV who have been on treatment for 12 months in rural South Africa. SAHARA J. 2013 Mar; 10(1):25–31. https://doi.org/10.1080/17290376.2013.807070 PMID: 23777555

44. Mwesigire DM, Martin F, Seeley J, Katamba A. Relationship between CD4 count and quality of life over time among HIV patients in Uganda: a cohort study. Health Qual Life Outcomes. 2015 Sep 15; 13:144. https://doi.org/10.1186/s12955-015-0332-3 PMID: 26370702

45. Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, et al. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PloS One. 2013; 8(12):e84173. https://doi.org/10.1371/journal.pone.0084173 PMID: 24367639

46. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PloS One. 2013; 8(5):e64604. https://doi.org/10.1371/journal.pone.0064604 PMID: 23741348

47. Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PloS One. 2014; 9(1):e85197. https://doi.org/10.1371/journal.pone.0085197 PMID: 24465503

48. Bert F, Gualano MR, Biancone P, Brescia V, Camussi E, Martorana M, et al. Cost-effectiveness of HIV screening in high-income countries: A systematic review. Health Policy. 2018 May; 122(5):533–47. https://doi.org/10.1016/j.healthpol.2018.03.007 PMID: 29606287